SMR Val Rosay
Saint-Didier-au-Mont-d'Or, France, 69370
Location status: Recruiting
Location contact
julie di marco, MD
CONTACT
julie di marco, MD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT06230796
To determine whether active cycling assisted by functional electrical stimulation (FES) Is more effective than active cycling on cardiovascular fitness in post stroke hemiparesis
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Saint-Didier-au-Mont-d'Or, France, 69370
Location status: Recruiting
julie di marco, MD
CONTACT
julie di marco, MD
PRINCIPAL_INVESTIGATOR
Design: In a monocentric, single-blind, randomized, controlled trial, hemiparetic post stroke patients will be randomized to receive FES-induced cycling training or placebo FES cycling.
Setting: Neurologic Rehabilitation Unit Interventions: 30 minutes of active leg cycling with or without FES applied to the paretic rectus femoris of quadriceps and to the biceps femoris and semitendinosus muscles and gluteus maximus, 3 times/weeks for 8 weeks. During training, participants will be seated on a FES-Cycle (Hepha Bike, Kurage): a cyclo-ergometer (Technogym) combined with a 8 channel controlled stimulator (Motimove-8).
In addition to the assigned group treatment, subjects will perform their own standard rehabilitation program.
Participants will be evaluated before training, after training, and at 3 month follow-up visit
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
30 minutes of active leg cycling with or without FES applied to the paretic rectus femoris of quadriceps and to the biceps femoris and semitendinosus muscles and gluteus maximus, 3 times/weeks for 8 weeks. During training, participants will be seated on a FES-Cycle (Hepha Bike, Kurage): a cyclo-ergometer (Technogym) combined with a 8 channel controlled stimulator (Motimove-8).
30 minutes of active leg cycling with SHAM FES applied to the paretic rectus femoris of quadriceps and to the biceps femoris and semitendinosus muscles and gluteus maximus, 3 times/weeks for 8 weeks. During training, participants will be seated on a FES-Cycle (Hepha Bike, Kurage): a cyclo-ergometer (Technogym) combined with a 8 channel controlled stimulator (Motimove-8).
Time frame: From enrollment to the end of treatment at 8 weeks
Comparison of the maximum oxygen consumption (VO2 peak in L/min) measured during an incremental maximum stress test on cyclo-ergometer between the end of training (M2) and inclusion (M0).
Time frame: 2 months
Comparison of the maximum power (in Watts) developed during the stress test on a cycloergometer between the end of the training (M2) and the inclusion (M0)
Time frame: 4 months
walking speed (10m walking test) and distance (6-minute walking test) measured at inclusion, after training (M2) ans follow-up (M4)
Time frame: 2 months
quadriceps muscular thickness measured with ultrasound at inclusion aand after the training
Time frame: 2 months
Middle Cerebral Artery Blood Flow Velocity During Exercise measured with transcranial Doppler ultrasound at inclusion (M0) and after the training (M2)
Time frame: 2 months
Paper test: Stroop and trail making test at inclusion and after training
Contact information is provided by the study sponsor or research team.
UGECAM Rhône-Alpes
Other
Effects of FES-cycling in Patients With Hemiparesis After Stroke
Acronym: AVCyclES
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05626894
Brain Diseases, Cardiovascular Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT06797154
Brain Diseases, Cardiovascular Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT06107010
Brain Diseases, Cardiovascular Diseases
Créteil, France
View Trial DetailsNCT06575140
Brain Diseases, Cardiovascular Diseases
Mexico City, Mexico
View Trial Details